Lifecore Biomedical Share Price Today

Lifecore Biomedical Q3 Results: Loss widens to $1.08 per share

Lifecore Biomedical reported a Q3 EPS of $(1.08), missing the $(0.28) estimate by 285.71%. Quarterly sales fell 27.97% YoY to $25.322 million, below the $26.699 million consensus. The loss per share widened significantly from $(0.28) in the same period last year. Revenue contraction outpaced the analyst expectations, signaling broader market challenges.

Kahn Swick & Foti probes Lifecore sale; joins Ademi in scrutiny

Kahn Swick & Foti investigates the adequacy of the $6.28 per share offer for Lifecore Biomedical. The probe joins an existing investigation by Ademi LLP into the Webster Equity Partners deal. Total potential consideration reaches $9.67 per share, including contingent value rights. Upfront cash represents a 49.5% premium to the September 25, 2026 closing price.

Lifecore Biomedical signs commercial site transfer deal for global pharma

Lifecore Biomedical signed a commercial site transfer agreement for a globally marketed injectable drug. The deal represents the company's seventh late-stage commercial program and eleventh addition in 2026. Commercial revenues from the program are expected to begin in 2028. The late-stage pipeline now contains thirteen programs targeting commercialization by end of 2028.

Lifecore Biomedical signs three new customer agreements for 2028 revenue

Lifecore Biomedical signed three new customer agreements on July 28, 2026, covering late-stage regenerative medicine and early-stage medical device programs. The deals expand the company's pipeline and are expected to contribute to 2028 revenue, reinforcing its position in high-growth markets.

Lifecore grants 3,500 RSUs to new employee under Nasdaq rule

Lifecore Biomedical granted 3,500 RSUs to a new employee effective July 13, 2026, under Nasdaq Listing Rule 5635(c)(4). The award, approved by the compensation committee, vests on the third anniversary of the grant date subject to continued employment.

Lifecore Biomedical signs seventh agreement in seven months

Lifecore Biomedical, Inc. signed an agreement with a global pharmaceutical company for the technical transfer and commercial manufacturing of an injectable suspension for neurological disorders. This marks the seventh late-stage addition to its pipeline in seven months, driven by demand for high-viscosity formulation capabilities.